{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:56:02Z","timestamp":1792158962401,"version":"4.4.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To address gaps in deep vein thrombosis (DVT) care, our health system implemented a pharmacist-led DVT clinic to standardize treatment, provide immediate access to pharmacy and vascular surgery services, and reduce emergency department (ED) and inpatient utilization for DVT management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, pre-post cohort study of a DVT clinic that centralized imaging, diagnosis, anticoagulant initiation, and pharmacy services into a single outpatient location. Patients diagnosed with a DVT between January 1, 2023, and December 31, 2024, were included. The co-primary outcomes were the proportion of systemwide DVT encounters occurring in the acute care setting compared before and after the DVT clinic opened (2023 vs 2024) and compared between patients seen in the clinic or not (2024 only). A \u03c72 test was used to analyze the co-primary outcomes, with significance defined as a P value of less than 0.05.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The pharmacist saw 205 patients across 363 visits in 2024. Compared to 2023 baseline data, the proportion of systemwide DVT encounters occurring in the ED in 2024 decreased from 88.6% to 53.3% (P &amp;lt; 0.001), while the rate of inpatient admission for DVT decreased from 25.5% to 13.9% (P &amp;lt; 0.001). Stratified analysis of the 2024 data demonstrated significantly lower acute care utilization for DVT among patients managed in the DVT clinic compared to those not seen, including for ED encounters (15.2% vs 91.5%; P &amp;lt; 0.001) and inpatient admissions (1.8% vs 26%; P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The pharmacist-led DVT clinic represents a transformative advancement in pharmacy practice, redefining the role of pharmacists in ambulatory care and establishing a replicable model to optimize value-based care that shifts treatment for appropriate populations from acute to outpatient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag337","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:46:02Z","timestamp":1791632762000},"source":"Crossref","is-referenced-by-count":0,"title":["Transforming value-based deep vein thrombosis care through a pharmacist-led clinic"],"prefix":"10.1093","author":[{"given":"Madison","family":"Yates","sequence":"first","affiliation":[{"name":"Cone Health , Greensboro, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Sfirlea","sequence":"additional","affiliation":[{"name":"Cone Health , Greensboro, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V Wells","family":"Brabham","sequence":"additional","affiliation":[{"name":"Cone Health , Greensboro, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Gazda","sequence":"additional","affiliation":[{"name":"Cone Health , Greensboro, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Schneider","sequence":"additional","affiliation":[{"name":"Cone Health , Greensboro, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"19","key":"2026101609311681500_zxag337-B1","doi-asserted-by":"publisher","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"2 suppl","key":"2026101609311681500_zxag337-B2","doi-asserted-by":"publisher","first-page":"e419S","DOI":"10.1378\/chest.11-2301","article-title":"Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"141","author":"Kearon","year":"2012","journal-title":"Chest"},{"issue":"2","key":"2026101609311681500_zxag337-B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"1","key":"2026101609311681500_zxag337-B4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11239-015-1317-0","article-title":"Guidance for the treatment of deep vein thrombosis and pulmonary embolism","volume":"41","author":"Streiff","year":"2016","journal-title":"J Thromb Thrombolysis"},{"issue":"3","key":"2026101609311681500_zxag337-B5","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/bloodadvances.2019001223","article-title":"Home vs hospital treatment of low-risk venous thromboembolism: a systematic review and meta-analysis","volume":"4","author":"Khatib","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2026101609311681500_zxag337-B6","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report\u2014executive summary","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"suppl 1","key":"2026101609311681500_zxag337-B7","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1182\/blood-2019-126844","article-title":"Change in admission rates among patients presenting to emergency departments with VTE and low risk of complications: a retrospective cohort study from 11 community hospitals","volume":"134","author":"Rhoades","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2026101609311681500_zxag337-B8","doi-asserted-by":"publisher","first-page":"e001123","DOI":"10.1136\/bmjoq-2020-001123","article-title":"Reducing emergency department visits in patients with deep vein thrombosis: introducing a standardised outpatient treatment pathway","volume":"10","author":"Wan","year":"2021","journal-title":"BMJ Open Qual"},{"issue":"6","key":"2026101609311681500_zxag337-B9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.18553\/jmcp.2007.13.6.475","article-title":"Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations","volume":"13","author":"Spyropoulos","year":"2007","journal-title":"J Manag Care Pharm"},{"issue":"4","key":"2026101609311681500_zxag337-B10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1177\/0897190012465953","article-title":"Optimizing transition of care through the facilitation of a pharmacist-managed deep vein thrombosis treatment program","volume":"26","author":"Davis","year":"2013","journal-title":"J Pharm Pract"},{"issue":"1","key":"2026101609311681500_zxag337-B11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4212\/cjhp.v74i1.3035","article-title":"Assessment of a pharmacist-led direct oral anticoagulant monitoring clinic","volume":"74","author":"Hach\u00e9","year":"2021","journal-title":"Can J Hosp Pharm"},{"issue":"4","key":"2026101609311681500_zxag337-B12","doi-asserted-by":"publisher","first-page":"100198","DOI":"10.1016\/j.rpth.2023.100198","article-title":"Advanced practice provider-led clinic for care transitions in newly diagnosed venous thromboembolism: establishment and utilization","volume":"7","author":"Frank","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"9","key":"2026101609311681500_zxag337-B13","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"2026101609311681500_zxag337-B14","author":"PQA"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag337\/71863572\/zxag337.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag337\/71863572\/zxag337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:31:21Z","timestamp":1792157481000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag337\/8909590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":14,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag337","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"article-number":"zxag337"}}